• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis (Small 11/2022)
Breast Cancer TreatmentIn article number2107550, Wassana Yantasee and co-workers develop polymer-decorated mesoporous silica nanoparticles for HER2-positive breast cancer treatment. This patented versatile platform can co-deliver multiple therapeutic classes to ensure that they reach the target cells at the same time to fully realize their synergy. Illustrated herein are nanoparticles with three drug cargos: HER2 antibody, HER2 siRNA, and chemotherapeutic docetaxel.
Source: Small - March 17, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz ‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee Tags: Cover Picture Source Type: research

Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis
This research paper describes a new therapeutic candidate based on a nanoparticle that co-delivers siRNA against human epidermal growth factor receptor type 2 (HER2), trastuzumab, and docetaxel to treat advanced HER2+ breast cancer. The nanotherapeutic is more effective and safer than the free drug counterparts. It inhibits drug-resistant orthotopic and brain-metastatic HER2+ breast tumors in mice. AbstractThe first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or pacli...
Source: Small - January 27, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz ‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee Tags: Research Article Source Type: research

CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in  vivo.
CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in vivo. Mol Med Rep. 2017 Jun 07;: Authors: Liu T, Wu X, Wang Y, Hou X, Jiang G, Wu T, Xie H, Xie M Abstract The co-delivery of a drug and a target gene has become a primary strategy in cancer therapy. Based on our previous study, a synthesized star‑shaped co‑polymer consisting of β‑cyclodextrin (CD) and a poly(L‑lysine) dendron (PLLD) was used to co-deliver docetaxel (DOC) and matrix metalloproteinase 9 (MMP‑9) small interfering RNA, via CD‑PLLD/DOC/MMP‑9 complexes, into mice implanted with HN...
Source: Molecular Medicine Reports - October 29, 2017 Category: Molecular Biology Tags: Mol Med Rep Source Type: research